Cancer Treatment Application of the Aethlon Hemopurifier(R) Published in Journal of Translational Medicine
2008-07-24 06:00:00
Cancer Treatment Application of the Aethlon Hemopurifier(R) Published in Journal of Translational Medicine
SAN DIEGO–(EMWNews)–Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that a peer reviewed
scientific paper coauthored by Aethlon researchers has been published in
the Journal of Translational Medicine. The paper entitled, “Exosomes
as a Tumor Immune Escape Mechanism: Possible Therapeutic Implications”
discusses the mechanism by which exosomes released by cancerous tumors
are able to kill off immune cells in cancer patients. The paper further
discusses the novel therapeutic approach of the Aethlon Hemopurifier®
to capture and inhibit the spread of such immunosuppressive exosomes in
cancer patients. The abstract and complete article are available to be
accessed online at: www.translational-medicine.com/content/6/1/37.
“As we continue to progress the infectious
disease applications of our Hemopurifier®, the
Journal of Translational Medicine publication recognizes and reinforces
the additional potential of the Hemopurifier®
within the $43 billion cancer therapy market,”
stated Aethlon Chairman and CEO, James A. Joyce. “We
thank the numerous researchers who participated in coauthoring the paper
with our research team,” concluded Joyce.
Aethlon previously disclosed that researchers discovered that the
Hemopurifier® is effective in capturing
exosomes that are released by solid tumors, lymphomas, and leukemia.
Exosomes induce T-cell apoptosis (programmed cell death), and block
T-cell signaling, proliferation, and cytokine production. High
concentrations of circulating exosomes correlate with reduced T-cell
production and tumor progression in cancer patients. In studies led by
Dr. Douglas Taylor at the University of Louisville, 60% of circulating
exosomes were removed from the blood of ovarian cancer patients during
first pass (approximately 10-minutes) through a small scale Hemopurifier®.
The capture data was consistent over the course of five different in
vitro blood studies. The ability to reduce circulating exosomes would
likely reverse immune suppression and increase patient responsiveness to
both immunotherapy and chemotherapy. Dr. Taylor is a recognized
authority on the causative effects of immune suppression in cancer
patients. He is credited with the initial characterization of exosomes
and is the leading peer reviewed author on the subject.
About Aethlon Medical
Aethlon Medical is the developer of the Hemopurifier®,
a first-in-class medical device designed to treat infectious disease.
The Hemopurifier® provides real-time
therapeutic filtration of infectious viruses and immunosuppressive
particles, and is positioned to address the treatment of drug and
vaccine resistant viruses. Additionally, the device holds promise in
cancer care, as research studies have verified the Hemopurifier®
is able to capture immunosuppressive particles secreted by tumors. The
Hemopurifier® is designed to act both as a
stand-alone therapeutic, and as an adjunct treatment to enhance clinical
benefit of established therapies. Pre-clinical studies conducted by
researchers representing leading government and non-government health
organizations both in the United States and abroad have documented the
effectiveness of the Hemopurifier® in
capturing from circulation the viruses that constitute pandemic threats,
including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever
(DHF) from circulation. The company is conducting studies to support the
use of the Hemopurifier® as a broad-spectrum
treatment countermeasure against bioterror threats, including Smallpox,
and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and
commercialization initiatives in the United States are presently focused
on bioterror threats, while international initiatives are directed
toward naturally evolving pandemic threats, and chronic infectious
disease conditions including the Human Immunodeficiency Virus (HIV) and
Hepatitis-C (HCV). Aethlon demonstrated the safety of the Hemopurifier®
in a 24-treatment human study at the Apollo Hospital in Delhi, India,
and is currently conducting further human studies at the Fortis
Hospital, also located in Delhi. The company has submitted an
investigational device exemption (IDE) to the U.S. Food and Drug
Administration (FDA) to advance the Hemopurifier®
as a broad-spectrum treatment countermeasure against category “A”
bioterror threats. Additional information regarding Aethlon Medical and
its Hemopurifier®
technology is available online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
Aethlon Medical, Inc. to be materially different from any future
results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company’s
ability to raise capital when needed, the Company’s
ability to complete the development of its planned products, the ability
of the Company to obtain FDA and other regulatory approvals permitting
the sale of its products, the Company’s
ability to manufacture its products and provide its services, the impact
of government regulations, patent protection on the Company’s
proprietary technology, product liability exposure, uncertainty of
market acceptance, competition, technological change, and other risk
factors. In such instances, actual results could differ materially as a
result of a variety of factors, including the risks associated with the
effect of changing economic conditions and other risk factors detailed
in the Company’s Securities and Exchange
Commission filings.
|
Aethlon Medical, Inc. Director, Communications A. Joyce, 858-459-7800, x301 |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
